{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:25Z","timestamp":1792787905030,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lund University","id":[{"id":"https:\/\/ror.org\/012a77v79","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>[18\u00a0F]-fluorodeoxyglucose (FDG) positron emission tomography combined with computed tomography (PET-CT) is used for staging and treatment response evaluation in patients with locally advanced cervical cancer. While the maximum standardised uptake value (SUVmax) is a commonly used PET parameter, volume-based parameters (metabolic tumour volume (MTV) and total lesion glycolysis (TLG)) may offer superior predictive value. This study aimed to investigate the predictive value of different treatment response outcomes assessed with PET-CT, using both standard and volume-based PET parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 133 patients with locally advanced cervical cancer treated with (chemo)radiotherapy who underwent PET-CT pre- and post-treatment. SUVmax, MTV and TLG were semi-automatically extracted from all scans, including tumour, lymph nodes and metastases. Treatment response was classified as complete metabolic response (CMR) (complete resolution of FDG uptake in all lesions), partial metabolic response (PMR) (&gt;\u200925% reduction of SUVmax\/MTV\/TLG), progressive metabolic disease (PMD) (&gt;\u200925% increase of SUVmax\/MTV\/TLG or appearance of new FDG-avid lesions) or stable disease (SD) (does not qualify for CMR, PMR or PMD). The three PET-parameters were analysed separately. PMR and SD were analysed as one group due to limited number of events. Associations between treatment response and overall survival (OS) as well as recurrence (binary variable) were analysed through Cox and logistic regression models, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For recurrence (binary variable), the odds ratio (OR) was 1.2 for patients with PMR\/SD for SUVmax, MTV and TLG, while in the group of patients with PMD, it was 1.7 for SUVmax and 1.8 for MTV and TLG, using CMR as reference (i.e. for CMR, the OR is 1.0). The hazard ratio (HR) for OS was 4.0 for patients with PMR\/SD and 16.0 for those with PMD, based on SUVmax; for MTV and TLG, HRs were 2.9 for patients with PMR\/SD and 16.0 for those with PMD, using CMR as reference (HR 1.0). C-index from adjusted Cox models were comparable: 0.84 for SUVmax, and 0.86 for both MTV and TLG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FDG-PET\/CT-based assessment of treatment response is a strong predictor of recurrence and overall survival in locally advanced cervical cancer. SUVmax, MTV, and TLG demonstrated similar predictive performance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12880-026-02772-8","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:35:21Z","timestamp":1789745721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FDG-PET\/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6148-8033","authenticated-orcid":false,"given":"Maria","family":"Markus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1116-5199","authenticated-orcid":false,"given":"Hanna","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5315-4423","authenticated-orcid":false,"given":"Maria","family":"Bjurberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8129-3228","authenticated-orcid":false,"given":"David","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-303X","authenticated-orcid":false,"given":"Elin","family":"Tr\u00e4g\u00e5rdh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"issue":"2","key":"2772_CR1","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197\u2013206.","journal-title":"Lancet Glob Health"},{"issue":"Suppl 2","key":"2772_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ijgo.12611","volume":"143","author":"N Bhatla","year":"2018","unstructured":"Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):22\u201336.","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"2772_CR3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.2214\/AJR.19.21819","volume":"214","author":"M Saleh","year":"2020","unstructured":"Saleh M, Virarkar M, Javadi S, Elsherif SB, de Castro Faria S, Bhosale P. Cervical Cancer: 2018 Revised International Federation of Gynecology and Obstetrics Staging System and the Role of Imaging. AJR Am J Roentgenol. 2020;214(5):1182\u201395.","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"2772_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0360-3016(02)04287-6","volume":"55","author":"PW Grigsby","year":"2003","unstructured":"Grigsby PW, Siegel BA, Dehdashti F, Mutch DG. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys. 2003;55(4):907\u201313.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2772_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cpet.2022.03.006","volume":"17","author":"RV Parghane","year":"2022","unstructured":"Parghane RV, Basu S. PET-CTBased Quantitative Parameters for Assessment of Treatment Response and Disease Activity in Cancer and Noncancerous Disorders. PET Clin. 2022;17(3):465\u201378.","journal-title":"PET Clin"},{"issue":"9","key":"2772_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/RLU.0000000000001269","volume":"41","author":"JW Yoon","year":"2016","unstructured":"Yoon JW, Kim S, Kim SW, Kim YT, Kang WJ, Nam EJ. PET\/CT Response Criteria (European Organization for Research and Treatment of Cancer) Predict Survival Better Than Response Evaluation Criteria in Solid Tumors in Locally Advanced Cervical Cancer Treated With Chemoradiation. Clin Nucl Med. 2016;41(9):677\u201382.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"2772_CR7","first-page":"e5422","volume":"11","author":"Z Nasir","year":"2019","unstructured":"Nasir Z, Mahmood T, Adel H, Nausheen S, Hamid S, Sattar A, Manohar M. Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors. Cureus. 2019;11(8):e5422.","journal-title":"Cureus"},{"issue":"11","key":"2772_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00066-025-02452-6","volume":"201","author":"L Draghini","year":"2025","unstructured":"Draghini L, Costantini S, Ippolito E, De Felice F, Caroli A, Navarria F, Piccolo F, Fionda B, De Sanctis V, Macchia G, Vicenzi L. Potential prognostic role of the 18F-FDG PET\/CT metabolic response in locally advanced cervical cancer after definitive chemoradiotherapy: a narrative review. Strahlenther Onkol. 2025;201(11):1219\u201326.","journal-title":"Strahlenther Onkol"},{"issue":"8","key":"2772_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573\u20137. Erratum in: Ann Intern Med. 2008;148(2):168.","journal-title":"Ann Intern Med"},{"key":"2772_CR10","unstructured":"Regionala cancercentrum i samverkan. Nationellt v\u00e5rdprogram f\u00f6r livmoderhalscancer och vaginalcancer. Version 2.2 [Internet]. Stockholm: Regionala cancercentrum i samverkan; 2024 [cited 2025 Jun 9]. Available from: https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/livmoderhals-och-vaginalcancer\/vardprogram\/."},{"issue":"2","key":"2772_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/0284186X.2023.2181100","volume":"62","author":"M Markus","year":"2023","unstructured":"Markus M, Sartor H, Bjurberg M, Tr\u00e4g\u00e5rdh E. Metabolic parameters of [18F]FDG PET-CT before and after radiotherapy may predict survival and recurrence in cervical cancer. Acta Oncol. 2023;62(2):180\u20138.","journal-title":"Acta Oncol"},{"issue":"13","key":"2772_CR12","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35(13):1773\u201382.","journal-title":"Eur J Cancer"},{"issue":"11","key":"2772_CR13","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1200\/JCO.2004.09.035","volume":"22","author":"PW Grigsby","year":"2004","unstructured":"Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004;22(11):2167\u201371.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2772_CR14","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.3802\/jgo.2019.30.e66","volume":"30","author":"YJ Kim","year":"2019","unstructured":"Kim YJ, Han S, Kim YS, Nam JH. Prognostic value of post-treatment \u00b9\u2078F-fluorodeoxyglucose positron emission tomography in uterine cervical cancer patients treated with radiotherapy: a systematic review and meta-analysis. J Gynecol Oncol. 2019;30(5):e66.","journal-title":"J Gynecol Oncol"},{"issue":"12","key":"2772_CR15","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00259-018-4077-1","volume":"45","author":"GM Lima","year":"2018","unstructured":"Lima GM, Matti A, Vara G, Dondi G, Naselli N, De Crescenzo EM, Morganti AG, Perrone AM, De Iaco P, Nanni C, Fanti S. Prognostic value of posttreatment 18F-FDG PET\/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. Eur J Nucl Med Mol Imaging. 2018;45(12):2139\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2772_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1053\/j.semnuclmed.2019.06.007","volume":"49","author":"N Gandy","year":"2019","unstructured":"Gandy N, Arshad MA, Park WE, Rockall AG, Barwick TD. FDG-PET Imaging in Cervical Cancer. Semin Nucl Med. 2019;49(6):461\u201370.","journal-title":"Semin Nucl Med"},{"key":"2772_CR17","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1097\/RLU.0000000000002188","volume":"43","author":"SH Son","year":"2018","unstructured":"Son SH, Jeong SY, Chong GO, Lee YH, Park SH, Lee CH, et al. Prognostic value of pretreatment metabolic PET parameters in cervical cancer patients with metabolic complete response after concurrent chemoradiotherapy. Clin Nucl Med. 2018;43:e296\u2013303.","journal-title":"Clin Nucl Med"},{"key":"2772_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ygyno.2012.08.006","volume":"127","author":"S Beriwal","year":"2012","unstructured":"Beriwal S, Kannan N, Sukumvanich P, Richard SD, Kelley JL, Edwards RP, et al. Complete metabolic response after definitive radiation therapy for cervical cancer: patterns and factors predicting for recurrence. Gynecol Oncol. 2012;127:303\u20136.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2772_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/IGC.0000000000000038","volume":"24","author":"VS Dhull","year":"2014","unstructured":"Dhull VS, Sharma P, Sharma DN, Maharjan S, Suman Kc S, Patel C, Bal C, Kumar R. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival? Int J Gynecol Cancer. 2014;24(2):312\u201320.","journal-title":"Int J Gynecol Cancer"},{"issue":"19","key":"2772_CR20","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1001\/jama.298.19.2289","volume":"298","author":"JK Schwarz","year":"2007","unstructured":"Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA. 2007;298(19):2289\u201395.","journal-title":"JAMA"},{"issue":"4","key":"2772_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00259-016-3537-8","volume":"44","author":"A Scarsbrook","year":"2017","unstructured":"Scarsbrook A, Vaidyanathan S, Chowdhury F, Swift S, Cooper R, Patel C. Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2017;44(4):581\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2772_CR22","doi-asserted-by":"publisher","first-page":"030201","DOI":"10.11613\/BM.2017.030201","volume":"27","author":"A Mlinari\u0107","year":"2017","unstructured":"Mlinari\u0107 A, Horvat M, \u0160upak Smol\u010di\u0107 V. Dealing with the positive publication bias: Why you should really publish your negative results. Biochem Med (Zagreb). 2017;27(3):030201.","journal-title":"Biochem Med (Zagreb)"},{"issue":"4","key":"2772_CR23","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/cancers13040869","volume":"13","author":"K Hirata","year":"2021","unstructured":"Hirata K, Tamaki N, Quantitative. FDG PET Assessment for Oncology Therapy. Cancers (Basel). 2021;13(4):869.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2772_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"52","author":"HJ Im","year":"2018","unstructured":"Im HJ, Bradshaw T, Solaiyappan M, Cho SY. Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? Nucl Med Mol Imaging. 2018;52(1):5\u201315.","journal-title":"Nucl Med Mol Imaging"},{"issue":"12","key":"2772_CR25","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00259-015-3112-8","volume":"42","author":"S Siva","year":"2015","unstructured":"Siva S, Deb S, Young RJ, Hicks RJ, Callahan J, Bressel M, Mileshkin L, Rischin D, Bernshaw D, Narayan K. \u00b9\u2078F-FDG PET\/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. Eur J Nucl Med Mol Imaging. 2015;42(12):1825\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2772_CR26","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.3802\/jgo.2021.32.e74","volume":"32","author":"C Onal","year":"2021","unstructured":"Onal C, Guler OC, Reyhan M, Yapar AF. Long-term outcomes of cervical cancer patients with complete metabolic response after definitive chemoradiotherapy. J Gynecol Oncol. 2021;32(5):e74.","journal-title":"J Gynecol Oncol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02772-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02772-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02772-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:54:32Z","timestamp":1789746872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02772-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2772"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02772-8","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Regional Ethical Review Board at Lund (a division of the Swedish Ethical Review Authority) approved this study (#2016\/417, #2018\/753 and #2020\u201302524). The study was performed in accordance with the Declaration of Helsinki. Written informed consent was signed by all patients included from 2016. Informed consent before 2016 was waived by the Ethical Review Board.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was signed by all participants.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"458"}}